Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026

Why It Matters

Validating CKAP2 as a druggable target opens a new therapeutic avenue for multiple cancer types, potentially expanding the oncology pipeline. The data also showcase Soley’s AI‑driven discovery platform as a catalyst for rapid, first‑in‑class drug identification.

Key Takeaways

• STX-6398 shows selective anti‑tumor activity in 300‑cell line panel.
• Efficacy linked to CKAP2 protein abundance across hematologic and solid tumors.
• Oral dosing achieved dose‑dependent tumor regression in lung and colon xenografts.
• Preclinical safety profile indicates good tolerability and favorable toxicity.
• Soley leverages AI‑driven platform to discover first‑in‑class CKAP2 modulators.

Pulse Analysis

The cytoskeleton‑associated protein 2 (CKAP2) has long been labeled “undruggable” due to its intrinsically disordered structure, yet it plays a pivotal role in cell division and metastatic signaling. By targeting CKAP2, researchers aim to disrupt multiple oncogenic pathways simultaneously, offering a strategic advantage over single‑target agents that tumors can often bypass. The emergence of a small‑molecule modulator like STX‑6398 signals a paradigm shift, suggesting that even the most elusive proteins can become actionable with the right chemistry and biological insight.

Soley’s preclinical program highlights the translational potential of CKAP2 inhibition. In a comprehensive 300‑cell line screen, sensitivity to STX‑6398 aligned tightly with CKAP2 expression, establishing a clear biomarker‑driven strategy for patient selection. Mechanistic assays revealed downstream suppression of focal adhesion kinase signaling, impaired microtubule dynamics, and cell‑cycle arrest, while in vivo xenograft studies confirmed oral dosing could shrink tumors in lung and colon models without overt toxicity. These results not only validate the compound’s efficacy but also demonstrate a tolerable safety window, a critical hurdle for advancing to first‑in‑human trials.

Beyond the science, Soley’s integration of AI, high‑content imaging, and cloud‑scale computing accelerates the discovery of such first‑in‑class candidates. By converting cellular stress responses into actionable drug targets, the platform can rapidly iterate on chemistry and predict clinical relevance, shortening the traditional development timeline. If STX‑6398 progresses successfully, it could diversify the oncology market, offering a novel option for CKAP2‑expressing tumors and reinforcing the value of AI‑enabled biotech ventures. Investors and clinicians alike will watch forthcoming IND filings closely as a barometer for the broader applicability of CKAP2 modulation.